Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorsIra Tabas, Lale Ozcan
Estimating the term…
The present invention relates to methods of treating or preventing a metabolic disorder in a subject, methods of treating or preventing coronary artery disease in a subject with a metabolic disorder, as well as methods of reducing hepatic glucose production in a subject. Such methods include, but are not limited to, the administration to the subject of inhibitors or activators of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1, Dach2, or any combination thereof. The invention also provides methods of identifying a compound that inhibits the activity of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach2, or reduces the activity and/or activation of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach, or activates CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach2.
A method of treating a metabolic disorder in a subject in need thereof, wherein the metabolic disorder is induced by obesity and is selected from the group consisting of Type 2 diabetes, insulin resistance, and metabolic syndrome, the method comprising reducing the activity of MAP kinase activated protein kinase 2/MAP kinase activated protein kinase 3 (MK2/3) by administering to the subject an inhibitor of MK2/3, thereby treating the disorder, wherein the inhibitor of MK2/3 is a small molecule.
A method of treating hyperinsulinemia associated with a metabolic disorder in a subject in need thereof, wherein the metabolic disorder is induced by obesity and selected from the group consisting of Type 2 diabetes, insulin resistance, and metabolic syndrome, the method comprising reducing the activity of MK2/3 by administering to the subject an inhibitor of MK2/3, thereby treating the hyperinsulinemia associated with the disorder, wherein the inhibitor of MK2/3 is a small molecule.
A method of treating hyperglycemia associated with a metabolic disorder in a subject in need thereof, wherein the metabolic disorder is induced by obesity and selected from the group consisting of Type 2 diabetes, insulin resistance, and metabolic syndrome, the method comprising reducing the activity of MK2/3 by administering to the subject an inhibitor of MK2/3, thereby treating the hyperglycemia associated with the disorder, wherein the inhibitor of MK2/3 is a small molecule.
Dependencies are inferred from the claim text.